RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Puma Biotechnology Stock

Puma Biotechnology ROCE 2024

Puma Biotechnology ROCE

0.62

Ticker

PBYI

ISIN

US74587V1070

WKN

A1J643

In 2024, Puma Biotechnology's return on capital employed (ROCE) was 0.62, a -43.51% increase from the 1.1 ROCE in the previous year.

Puma Biotechnology Aktienanalyse

What does Puma Biotechnology do?

Puma Biotechnology Inc. is a biopharmaceutical company based in Los Angeles. It was founded in 2010 and initially focused on the development of innovative cancer treatments. Since then, the company has significantly expanded and now offers a wide range of products and services all centered around cancer treatment. The company's business model revolves around developing drugs that address the need for novel and effective therapies to treat cancer. Puma Biotechnology Inc. is a leading player in this field and has already brought several successful products to market. One of the company's most well-known cancer treatments is Neratinib (also known as Nerlynx), which is used to treat breast cancer. Nerlynx received FDA approval in July 2017. Puma Biotechnology Inc. was founded in 2010 by Alan H. Auerbach, who had previously founded the biopharmaceutical company Cougar Biotechnology and successfully sold it to Johnson & Johnson. The history of Puma Biotechnology Inc. is marked by continuous growth. After its founding, the company acquired exclusive rights to develop neratinib for the treatment of breast cancer. The company has since conducted numerous studies and collected clinical data to prove the efficacy and safety of Nerlynx. After years of research, the medication finally received FDA approval in 2017. Puma Biotechnology Inc. has expanded its offerings since its founding and now offers a wide range of products and services centered around cancer treatment. One of the company's main areas of focus is research and development of cancer treatments. Puma Biotechnology Inc. continuously works on developing new drugs and therapies for a variety of cancer types, including breast cancer, lung cancer, and leukemia. The company is also involved in the production and marketing of pharmaceuticals. Neratinib is the company's most well-known product, but Puma Biotechnology Inc. has also brought other cancer treatments to the market. Additionally, Puma Biotechnology Inc. offers a wide range of services in the field of cancer treatment. The company is involved in the development of diagnostics and preventative measures and also offers training and consultations for doctors and patients. Nerlynx is Puma Biotechnology Inc.'s most well-known product and is now distributed worldwide. The medication is an oral therapeutic used for the adjuvant treatment of early-stage HER2-positive breast cancer in adults following adequate standard adjuvant therapy. It is taken by women who have already undergone chemotherapy, surgery, and radiation therapy. Neratinib works to prevent cancer recurrences by targeting the HER2 receptor, which normally promotes cancer cell growth. The medication blocks these receptors and can therefore inhibit tumor growth. In addition, Puma Biotechnology Inc. has also brought other products to the market, including Ribociclib, which is used in combination with other medications to treat ER-positive, HER2-negative breast cancer. In conclusion, Puma Biotechnology Inc. is a unique and emerging company with a focus on cancer treatments. Since its founding in 2010, the company has become a leading player in cancer combat. Puma Biotechnology Inc. is involved in the development of innovative therapeutic approaches, has achieved numerous medical successes, and brought many promising medications to the market. With Nerlynx, the company has introduced an effective medication for the treatment of breast cancer, and its potential is far from being realized. The company will undoubtedly play an important role in the treatment of cancer in the future. Puma Biotechnology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Puma Biotechnology's Return on Capital Employed (ROCE)

Puma Biotechnology's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Puma Biotechnology's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Puma Biotechnology's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Puma Biotechnology’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Puma Biotechnology stock

What is the ROCE (Return on Capital Employed) of Puma Biotechnology this year?

The ROCE of Puma Biotechnology is 0.62 undefined this year.

How has the ROCE (Return on Capital Employed) of Puma Biotechnology developed compared to the previous year?

The ROCE of Puma Biotechnology has increased by -43.51% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Puma Biotechnology?

A high Return on Capital Employed (ROCE) indicates that Puma Biotechnology has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Puma Biotechnology?

A low ROCE (Return on Capital Employed) can indicate that Puma Biotechnology has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Puma Biotechnology impact the company?

An increase in the ROCE of Puma Biotechnology can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Puma Biotechnology affect the company?

A decrease in ROCE of Puma Biotechnology can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Puma Biotechnology?

Some factors that can affect Puma Biotechnology's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Puma Biotechnology so important for investors?

The ROCE of Puma Biotechnology is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Puma Biotechnology take to improve the ROCE?

To improve the ROCE, Puma Biotechnology can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Puma Biotechnology pay?

Over the past 12 months, Puma Biotechnology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Puma Biotechnology is expected to pay a dividend of 0 USD.

What is the dividend yield of Puma Biotechnology?

The current dividend yield of Puma Biotechnology is .

When does Puma Biotechnology pay dividends?

Puma Biotechnology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Puma Biotechnology?

Puma Biotechnology paid dividends every year for the past 0 years.

What is the dividend of Puma Biotechnology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Puma Biotechnology located?

Puma Biotechnology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Puma Biotechnology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Puma Biotechnology from 11/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/9/2024.

When did Puma Biotechnology pay the last dividend?

The last dividend was paid out on 11/9/2024.

What was the dividend of Puma Biotechnology in the year 2023?

In the year 2023, Puma Biotechnology distributed 0 USD as dividends.

In which currency does Puma Biotechnology pay out the dividend?

The dividends of Puma Biotechnology are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Puma Biotechnology

Our stock analysis for Puma Biotechnology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Puma Biotechnology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.